SELB Split History

Selecta Biosciences (SELB) has 3 splits in our SELB split history database. The first split for SELB took place on March 01, 1996. This was a 3 for 1 split, meaning for each share of SELB owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 3000 share position following the split. SELB's second split took place on June 22, 1998. This was a 1 for 8 reverse split, meaning for each 8 shares of SELB owned pre-split, the shareholder now owned 1 share. For example, a 3000 share position pre-split, became a 375 share position following the split. SELB's third split took place on December 08, 1999. This was a 2 for 1 split, meaning for each share of SELB owned pre-split, the shareholder now owned 2 shares. For example, a 375 share position pre-split, became a 750 share position following the split.

When a company such as Selecta Biosciences splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. When a company such as Selecta Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the SELB split history from start to finish, an original position size of 1000 shares would have turned into 750 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Selecta Biosciences shares, starting with a $10,000 purchase of SELB, presented on a split-history-adjusted basis factoring in the complete SELB split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	06/23/2016
End date:	06/07/2023
Start price/share:	$14.03
End price/share:	$1.36
Dividends collected/share:	$0.00
Total return:	-90.31%
Average Annual Total Return:	-28.49%
Starting investment:	$10,000.00
Ending investment:	$969.51
Years:	6.96

About Selecta Biosciences

Selecta Biosciences is a clinical-stage biopharmaceutical company. Co.'s ImmTOR® platform encapsulates rapamycin, also known as sirolimus, a Food and Drug Administration approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance. By combining ImmTOR with antigens of interest, Co.'s immune tolerance platform restores self-tolerance to auto-antigens in autoimmune diseases, amplify the ability of biologics (including gene therapies) and mitigate the formation of anti-drug antibodies against biologic drugs. According to our SELB split history records, Selecta Biosciences has had 3 splits.